A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Exclusion criteria

• ✕. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).
• ✕. Prior systemic chemotherapy within 2 weeks of planned start of study drug.
• ✕. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required.
• ✕. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.
• ✕. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.
• ✕. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).
• ✕. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL/SCNSL: no greater than 40 mg/day prednisone, or equivalent. Patients with PCNSL/SCNSL using greater than 20 mg/day prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg/day prednisone or equivalent.
• ✕. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug